lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections

Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde

Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation

Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study

Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption

A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6

C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Wei Chen | Pharmacology | Best Researcher Award

Prof. Wei Chen, Fudan University, China

Prof. Wei Chen is an Associate Professor at Fudan University, specializing in neuroscience and pharmacology. He earned his Ph.D. in Pharmacy from Fudan University and completed postdoctoral research at Stanford University. His work focuses on neuroregeneration, metabolic reprogramming, and precision medicine, with numerous high-impact publications in Nature Communications, Phytomedicine, and Advanced Biology. Prof. Chen has received multiple prestigious awards, including the National Scholarship and the Excellence Award at the International Forum of Precision Medicine. His innovative contributions span both basic research and clinical applications in neuropharmacology and renal therapy.

Publication Profile

Education

Prof. Wei Chen 🧠💊 is an esteemed Associate Professor at Fudan University, Shanghai, China, serving since September 2022. Prior to this, he was a Postdoctoral Scholar in Neuroscience at Stanford University, Palo Alto, USA (2019–2022), where he advanced cutting-edge research in brain science. Prof. Chen earned his Ph.D. in Pharmacy from Fudan University in 2019, following his M.D. in Pharmacy from the Second Military Medical University (2016) and Anhui Medical University (2013). With a solid foundation in pharmaceutical sciences and neuroscience, his academic journey reflects a commitment to innovation, discovery, and excellence in health research and education 🌍📚.

Awards

Prof. Wei Chen 🏅🎓 has been recognized with numerous prestigious awards and fellowships throughout his academic journey. In 2019, he was honored as one of the Excellent Graduates in Shanghai and received the “Warm Heart” Scholarship 💖. He earned the esteemed National Scholarship twice, in both 2018 and 2017, acknowledging his outstanding academic performance 📘. He also received the Excellence Award at the 2017 International Academic and Industrial Forum of Precision Medicine 🧬. Earlier, he was awarded the Best Student Award in 2016 🥇 and secured third prize in the Million College Students Science Entrepreneurship Competition in Anhui Province in 2012 💡🏆.

Research Focus

Wei Chen is a prominent researcher with a diverse focus on biomedicine, molecular therapy, and gene therapy. His work primarily explores the treatment of neurodegenerative disorders, kidney injury, liver disease, and cancer. He specializes in immune modulation, particularly through interleukin-22 (IL-22), and metabolic reprogramming to treat various diseases. His research also delves into neuroprotection, cellular regeneration, and inflammatory responses, utilizing innovative approaches like gene delivery and nanoparticle therapy. His contributions aim to transform therapeutic strategies, especially in complex conditions like pancreatic cancer and neurodegeneration.

Publication Top Notes

Qingyihuaji Formula reprograms metabolism to suppress pancreatic cancer growth and progression through LINC00346-OMA1-ATF4 signaling

Notoginsenoside Fc, a novel renoprotective agent, ameliorates glomerular endothelial cells pyroptosis and mitochondrial dysfunction in diabetic nephropathy through regulating HMGCS2 pathway

Maprotiline restores ER homeostasis and rescues neurodegeneration via Histamine Receptor H1 inhibition in retinal ganglion cells

The role of interleukin-22 in lung health and its therapeutic potential for COVID-19.

VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses

Interleukin-22 mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury

Interleukin-22 ameliorated acetaminophen-induced kidney injury by inhibiting mitochondrial dysfunction and inflammatory responses

Gene therapy for neurodegenerative disorders: advances, insights and prospects